BrosMed Medical Co., Ltd. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Tri-Wedge PTA Scoring Balloon Dilatation Catheter. “This represents yet another significant achievement in our effort to introduce BrosMed’s broad portfolio into the US market”, comments Scott J. Addonizio, Chief Operating Officer.
Sept. 30th, 2024 – BROSMED, an industry-leading multinational group in […]
2024 August 1st – BrosMed Medical is pleased to announce […]
BrosMed announced that it receives European Medical Device Regulation (MDR) certification for the New Generation PTA SC Balloon Dilatation Catheters (Brand Name: Polux™ Pro 014, Minerva™ Pro 018 and Atropos™ Pro 035).
Cordis and BrosMed launched ceremony for the localization strategy in China and will continue to uphold the mutual original commitment to innovation, maintain a patient-centered philosophy, persistently cultivate in the field of vascular intervention, and convey care to vascular disease patients worldwide.
The 37th Annual Meeting of the European Society for Vascular […]
This certification confirms BrosMed’s compliance with the high standards and regulatory requirements of most leading countries in the world.
BrosMed POT PTCA balloon is the world’s first dedicated balloon for proximal optimization technique (POT) and distal optimization technique (DOT) in bifurcation stenting.
Tiche™ 0.035” High Pressure PTA Balloon Dilatation Catheter is designed for the treatment of severely calcified peripheral vascular disease and challenging AV cases.
Rokku exchange device is dedicated to facilitate interventional medical device exchanges without losing wire position, and maximize the efficiency of complex cases during PCI procedures.
Tiche™ 0.035” PTA Balloon Dilatation Catheter has received the 510(k) clearance from the U.S. Food & Drug Administration on July 20, 2022.
To our clients, candidates and team members – thank you for coming on this journey with us. Your support makes Brosmed what it is today.
